Inhibition of DAMP actions in the tumoral microenvironment using lactoferrin-glycyrrhizin conjugate for glioblastoma therapy

[1]  Hyung Shik Kim,et al.  Gastrointestinally absorbable lactoferrin-heparin conjugate with anti-angiogenic activity for treatment of brain tumor. , 2023, Journal of controlled release : official journal of the Controlled Release Society.

[2]  M. Farag,et al.  Recent advances in glycyrrhizin metabolism, health benefits, clinical effects and drug delivery systems for efficacy improvement; a comprehensive review. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[3]  Dong Yun Lee,et al.  A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy , 2022, Journal of Nanobiotechnology.

[4]  A. Chatterjee,et al.  Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches , 2021, Journal of Pharmaceutical Investigation.

[5]  Yonghua Wang,et al.  Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration , 2021, Cancer cell international.

[6]  Dong Yun Lee,et al.  Milk protein-shelled gold nanoparticles with gastrointestinally active absorption for aurotherapy to brain tumor , 2021, Bioactive materials.

[7]  Saira A Khan,et al.  Epidemiology and prognostic factors of pediatric brain tumor survival in the US: Evidence from four decades of population data. , 2021, Cancer epidemiology.

[8]  T. Yoneda,et al.  The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone , 2020, Journal of bone oncology.

[9]  R. Mirzayans,et al.  Do TUNEL and Other Apoptosis Assays Detect Cell Death in Preclinical Studies? , 2020, International journal of molecular sciences.

[10]  Christoph H Emmerich,et al.  Improving target assessment in biomedical research: the GOT-IT recommendations , 2020, Nature reviews. Drug discovery.

[11]  Jia-You Fang,et al.  Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand , 2020, Biomaterials.

[12]  W. Lee,et al.  Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity , 2020, Experimental & Molecular Medicine.

[13]  Jun Wang,et al.  Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment , 2020, Frontiers in Immunology.

[14]  D. Kell,et al.  The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria , 2020, Frontiers in Immunology.

[15]  K. Umezawa,et al.  Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-κB Signaling Pathway , 2019, Front. Cell. Neurosci..

[16]  Hyun-Jong Cho.  Recent progresses in the development of hyaluronic acid-based nanosystems for tumor-targeted drug delivery and cancer imaging , 2019, Journal of Pharmaceutical Investigation.

[17]  Jianjun Chen,et al.  High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1α) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[18]  F. Deng,et al.  Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment , 2019, Journal of Experimental & Clinical Cancer Research.

[19]  Zhe Li,et al.  Pharmacokinetics of protein and peptide conjugates. , 2019, Drug metabolism and pharmacokinetics.

[20]  Bei Zhang,et al.  Glycyrrhizin, an HMGB1 inhibitor, exhibits neuroprotective effects in rats after lithium‐pilocarpine‐induced status epilepticus , 2018, The Journal of pharmacy and pharmacology.

[21]  Peng Cheng,et al.  High Mobility Group Box 1 (HMGB1) Predicts Invasion and Poor Prognosis of Glioblastoma Multiforme via Activating AKT Signaling in an Autocrine Pathway , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[22]  S. Chiang,et al.  HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer , 2018, Cell Death & Disease.

[23]  C. Marosi,et al.  The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Chuangui Wang,et al.  HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect , 2018, Cell Death & Disease.

[25]  Jun Hu,et al.  A Natural Glycyrrhizic Acid-Tailored Light-Responsive Gelator. , 2018, Chemistry, an Asian journal.

[26]  M. Kaksonen,et al.  Mechanisms of clathrin-mediated endocytosis , 2018, Nature Reviews Molecular Cell Biology.

[27]  Hyun Min Jeon,et al.  Regulation of Tumor Progression by Programmed Necrosis , 2018, Oxidative medicine and cellular longevity.

[28]  I. Khan,et al.  Glycyrrhizin induces reactive oxygen species-dependent apoptosis and cell cycle arrest at G0/G1 in HPV18+ human cervical cancer HeLa cell line. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  V Sakkalis,et al.  In Vitro/In Silico Study on the Role of Doubling Time Heterogeneity among Primary Glioblastoma Cell Lines , 2017, BioMed research international.

[30]  H. Chung,et al.  High‐mobility group box‐1 contributes tumor angiogenesis under interleukin‐8 mediation during gastric cancer progression , 2017, Cancer science.

[31]  Yang Shen,et al.  Cross-talk mechanism between endothelial cells and hepatocellular carcinoma cells via growth factors and integrin pathway promotes tumor angiogenesis and cell migration , 2017, Oncotarget.

[32]  Haichao Wang,et al.  Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer , 2017, Cell Research.

[33]  Y. Takayama,et al.  Role of CXC chemokine receptor type 4 as a lactoferrin receptor. , 2017, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[34]  J. Shankaranarayanan,et al.  Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice , 2016, Scientific Reports.

[35]  H. Gerós,et al.  Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase , 2016, Oncotarget.

[36]  A. Papavassiliou,et al.  Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression , 2016, Journal of Molecular Medicine.

[37]  Y. Kuo,et al.  Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. , 2015, International journal of pharmaceutics.

[38]  Yan-Yan Zhang,et al.  Clinical and prognostic significance of high-mobility group box-1 in human gliomas , 2014, Experimental and therapeutic medicine.

[39]  J. D. de Groot,et al.  Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects , 2014, Clinical Cancer Research.

[40]  Lei Xing,et al.  Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. , 2014, Molecular pharmaceutics.

[41]  S. Arévalo-Gallegos,et al.  Immunomodulatory effects of lactoferrin , 2014, Acta Pharmacologica Sinica.

[42]  M. Mildner,et al.  Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology , 2014, PloS one.

[43]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[44]  F. Abe,et al.  A lactoferrin-receptor, intelectin 1, affects uptake, sub-cellular localization and release of immunochemically detectable lactoferrin by intestinal epithelial Caco-2 cells. , 2013, Journal of biochemistry.

[45]  Kyu-Won Kim,et al.  The Anti‐Angiogenic Activities of Glycyrrhizic Acid in Tumor Progression , 2013, Phytotherapy research : PTR.

[46]  W. Tilley,et al.  False-positive TUNEL staining observed in SV40 based transgenic murine prostate cancer models , 2013, Transgenic Research.

[47]  W A Buurman,et al.  Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1 , 2013, Oncogene.

[48]  S. Szala,et al.  [HMGB1--its role in tumor progression and anticancer therapy]. , 2012, Postepy higieny i medycyny doswiadczalnej.

[49]  Cui Tang,et al.  Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. , 2012, Biomaterials.

[50]  A. Sieron,et al.  The Role of Glycyrrhizin, an Inhibitor of HMGB1 Protein, in Anticancer Therapy , 2012, Archivum Immunologiae et Therapiae Experimentalis.

[51]  H. Pass,et al.  Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. , 2012, Cancer research.

[52]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[53]  A. Brenner,et al.  Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors , 2011, Molecular Cancer Therapeutics.

[54]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[55]  G. Colombo,et al.  HMGB1-carbenoxolone interactions: dynamics insights from combined nuclear magnetic resonance and molecular dynamics. , 2011, Chemistry, an Asian journal.

[56]  Dai Fukumura,et al.  Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.

[57]  S. Akira,et al.  Human lactoferrin activates NF‐κB through the Toll‐like receptor 4 pathway while it interferes with the lipopolysaccharide‐stimulated TLR4 signaling , 2010, The FEBS journal.

[58]  Alan G. E. Wilson,et al.  Early Toxicology Signal Generation in the Mouse , 2010, Toxicologic pathology.

[59]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[60]  Hoguen Kim,et al.  Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers , 2009, Laboratory Investigation.

[61]  X. Yang,et al.  Proteomic screen defines the hepatocyte nuclear factor 1α-binding partners and identifies HMGB1 as a new cofactor of HNF1α , 2007, Nucleic acids research.

[62]  L. Riboni,et al.  HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration , 2008, Journal of Neuro-Oncology.

[63]  M. Zamai,et al.  Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. , 2007, Chemistry & biology.

[64]  E. Chavakis,et al.  High-Mobility Group Box 1 Activates Integrin-Dependent Homing of Endothelial Progenitor Cells , 2007, Circulation research.

[65]  Rongqin Huang,et al.  Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. , 2007, Journal of biomedical science.

[66]  L. Ulloa,et al.  High-mobility group box 1 (HMGB1) protein: friend and foe. , 2006, Cytokine & growth factor reviews.

[67]  T. Suhara,et al.  Pharmacokinetics and brain uptake of lactoferrin in rats. , 2006, Life sciences.

[68]  Thomas Ludwig,et al.  Glioblastoma cells release factors that disrupt blood-brain barrier features , 2004, Acta Neuropathologica.

[69]  S. Wieting,et al.  Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins , 2003, Journal of Cell Science.

[70]  A. Younes,et al.  Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders , 2003, Cancer.

[71]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[72]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[73]  V. Salmon,et al.  Lactoferrin Inhibits the Endotoxin Interaction with CD14 by Competition with the Lipopolysaccharide-Binding Protein , 1998, Infection and Immunity.